1.
The serum level of inflammatory markers in chronic and episodic migraine: a case-control study
by Martami, Fahimeh
Neurological sciences, 2018, Vol.39 (10), p.1741-1749
2.
TIPE2 regulates tumor-associated macrophages in skin squamous cell carcinoma
by Li, Xin
Tumor biology, 2015, Vol.37 (4), p.5585-5590
3.
Psoriasis
by Boehncke, Wolf-Henning, Prof
The Lancet (British edition), 2015, Vol.386 (9997), p.983-994
4.
Efficacy of TNF[alpha] blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis
by Johanna Callhoff
Annals of the rheumatic diseases, 2015, Vol.74 (6), p.1241
5.
Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-α antagonist therapy: safe re-initiation of TNF-α blockers after appropriate ant...
by Denis, B
Clinical microbiology and infection, 2008, Vol.14 (2), p.183-186
6.
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, doubl...
by Nash, Peter, Prof
The Lancet (British edition), 2017, Vol.389 (10086), p.2317-2327
7.
Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study
by Tian, Jianbo
The lancet oncology, 2020, Vol.21 (7), p.893-903
8.
S111 Altered neutrophil phenotypes in pulmonary arterial hypertension
by Dirir, O
Thorax, 2017, Vol.72 (Suppl 3), p.A68
9.
Circular RNA: A new star of noncoding RNAs
by Qu, Shibin
Cancer letters, 2015, Vol.365 (2), p.141-148
10.
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
by Griffiths, Christopher E M, Prof
The Lancet (British edition), 2015, Vol.386 (9993), p.541-551
11.
Axial spondyloarthritis
by Sieper, Joachim, Prof
The Lancet (British edition), 2017, Vol.390 (10089), p.73-84
12.
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-infer...
by Jørgensen, Kristin K, PhD
The Lancet (British edition), 2017, Vol.389 (10086), p.2304-2316
13.
327 B7-H3 Chimeric Antigen Receptor Modified T Cells Show Potent Anti-Tumor Activity in a Preclinical Model of Glioblastoma
by Chow, Kwong-Hon (Kevin)
Neurosurgery, 2017, Vol.64 (CN_suppl_1), p.272-272
14.
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial
by Colombel, Jean-Frederic
The Lancet (British edition), 2017, Vol.390 (10114), p.2779-2789
15.
Osteoarthritis
by Glyn-Jones, S, Prof
The Lancet (British edition), 2015, Vol.386 (9991), p.376-387
16.
New WHO recommendations on preoperative measures for surgical site infection prevention: an evidence-based global perspective
by Allegranzi, Benedetta, Dr
The Lancet infectious diseases, 2016, Vol.16 (12), p.e276-e287
17.
Dysbiotic gut microbiota causes transmissible Crohn's disease-like ileitis independent of failure in antimicrobial defence
by Schaubeck, Monika Monika
Gut, 2015, Vol.65 (2), p.225-237
18.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
by Smolen, Josef S
Annals of the rheumatic diseases, 2014, Vol.73 (3), p.492-509
19.
Reactivation histoplasmosis after treatment with anti-tumor necrosis factor α in a patient from a nonendemic area
by Jain, Vipul V
Respiratory medicine, 2006, Vol.100 (7), p.1291-1293
20.
Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
by Bachelez, Hervé, Prof
The Lancet (British edition), 2015, Vol.386 (9993), p.552-561
